AB SCIEX, a global leader in life science analytical technologies, announced that it is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world’s leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.
Leading researcher Tony Pawson, PhD, a Kyoto Prize-winning scientist, and his team at the Lunenfeld are focusing their biomedical studies on analyzing complex protein interactions and modifications in the pathways and processes of communication between cells. The Lunenfeld is at the forefront of using mass spectrometry technology to apply protein research to enhance the field of cell biology and provide new insights into human diseases.
Through this collaboration, Lunenfeld researchers are using the life science industry’s first mass spectrometry system that combines qualitative and quantitative analysis at high resolution, high speed and high sensitivity with accurate mass. The result will be new workflows and applications that will be made available to the global life science community when AB SCIEX launches the new platform later this year. These workflows and applications will help expand the use of mass spectrometry across the life sciences.
Date: April 22, 2010
Source: AB SCIEX
